Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 2/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.33 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892143 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4ENPC1GLA | |
| SCHEMBL891800 | 0.76 | TAAR1 (0.68) | ALDH1A1MAPTKDM4ENPC1GLA | |
| SCHEMBL891798 | 0.76 | TAAR1 (0.68) | ALDH1A1MAPTKDM4ENPC1GLA | |
| SCHEMBL17354777 | 0.75 | FBP1 (0.43) | ALDH1A1MAPTKDM4ENPC1GLA | |
| SCHEMBL1260529 | 0.73 | FBP1 (0.59) | ALDH1A1MAPTKDM4EFBP1HDAC2 | |
| SCHEMBL21574805 | 0.73 | FBP1 (0.59) | ALDH1A1MAPTKDM4EFBP1HDAC2 | |
| SCHEMBL1687898 | 0.73 | FBP1 (0.59) | ALDH1A1MAPTKDM4EFBP1HDAC2 | |
| SCHEMBL13799049 | 0.73 | FBP1 (0.59) | ALDH1A1MAPTKDM4EFBP1HDAC2 | |
| SCHEMBL8699093 | 0.73 | FBP1 (0.59) | ALDH1A1MAPTKDM4EFBP1HDAC2 | |
| SCHEMBL1687911 | 0.73 | FBP1 (0.59) | ALDH1A1MAPTKDM4EFBP1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445915-B1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | PHARMINOX LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-9024018-B2 | 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use | PHARMINOX LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| EP-2445915-A1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | Pharminox Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120083513-A1 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | US | disclosed |
| WO-2010149968-A1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | PHARMINOX LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083513-A1 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use | MKI67, CCNA1, CCNI | ALDH1A1 74/4885MAPT 3259/4885KDM4E 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.